Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Short term Debt (2018 - 2022)

Lipocine's Short term Debt history spans 5 years, with the latest figure at $1.5 million for Q1 2022.

  • For Q1 2022, Short term Debt fell 55.54% year-over-year to $1.5 million; the TTM value through Mar 2022 reached $1.5 million, down 55.54%, while the annual FY2021 figure was $2.3 million, 30.68% down from the prior year.
  • Short term Debt reached $1.5 million in Q1 2022 per LPCN's latest filing, down from $2.3 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $4.0 million in Q2 2021 to a low of $1.3 million in Q1 2018.
  • Average Short term Debt over 5 years is $2.7 million, with a median of $3.2 million recorded in 2020.
  • Peak YoY movement for Short term Debt: surged 148.66% in 2019, then crashed 55.54% in 2022.
  • A 5-year view of Short term Debt shows it stood at $3.3 million in 2018, then changed by 0.0% to $3.3 million in 2019, then changed by 0.0% to $3.3 million in 2020, then plummeted by 30.68% to $2.3 million in 2021, then plummeted by 35.86% to $1.5 million in 2022.
  • Per Business Quant, the three most recent readings for LPCN's Short term Debt are $1.5 million (Q1 2022), $2.3 million (Q4 2021), and $3.1 million (Q3 2021).